Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On

By Zacks Investment ResearchStock MarketsApr 12, 2021 09:36PM ET
www.investing.com/analysis/thermo-fisher-tmo-rides-on-end-markets-as-pandemic-rages-on-200572783
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
By Zacks Investment Research   |  Apr 12, 2021 09:36PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

On Apr 12, we issued an updated research report on Thermo Fisher Scientific, Inc. TMO. The company is rapidly boosting its inorganic growth profile. The most recent takeover was that of Brammer Bio. Its strong focus on the emerging markets is also encouraging. The stock has a Zacks Rank #3 (Hold).

Thermo Fisher has outperformed its industry in the past six months. The stock has gained 8.6% compared with the industry’s 5% rise.

In fourth-quarter 2020, the company delivered an outstanding quarterly performance with organic growth of 51%, leveraging on its capacity to extend support amid the pandemic. COVID-19 response revenues increased to $3.2 billion in the fourth quarter, bringing the full-year contribution to $6.6 billion driven by testing-related products and instruments.

The base business too grew 5% organically, registering another quarter of sequential improvement. Further, for 2020, the company generated $500 million of revenues from COVID-19-related vaccines and therapies support.

In terms of end market, pharma and biotech registered 25% growth in the fourth quarter on robust performance in bioproduction, pharma services, biosciences, and research and safety market channel businesses. In diagnostics and healthcare, the company experienced exceptionally high demand for COVID-19 testing and was able to deliver 200% growth.

Academic and government grew in high single digits as customers across the globe ramped up activity. The company saw particularly good growth across its chromatography and mass spectrometry businesses. In industrial and applied end market, following a series of dull quarters, the company returned to growth in the fourth quarter and grew in low single digits.

On the flip side, the COVID-19 headwinds impacted each of its end markets in varying degrees. Overall, the company saw significantly reduced customer activity due to work disruptions.

Thermo Fisher’s industrial and applied end market registered low single-digit growth in the fourth quarter. Customers in this end market were significantly affected by business disruptions due to the pandemic.

Foreign currency fluctuations and competitive landscape are the other major downsides.

Key Picks

Some better-ranked stocks from the broader medical space are Owens & Minor, Inc. OMI, BioRad Laboratories, Inc. BIO and LeMaitre Vascular, Inc. LMAT. While Owens & Minor sports a Zacks Rank #1 (Strong Buy), BioRad Laboratories and LeMaitre Vascular carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Owens & Minor has a projected long-term earnings growth rate of 15%.

BioRad Laboratories has a projected long-term earnings growth rate of 7%.

LeMaitre Vascular has an estimated long-term earnings growth rate of 10%.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Owens & Minor, Inc. (OMI): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

BioRad Laboratories, Inc. (BIO): Free Stock Analysis Report

LeMaitre Vascular, Inc. (LMAT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
 

Related Articles

Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email